Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model

References

• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62–68. PubMed PMID: 25838374.
   PubMed Web of Science ®Google Scholar
• Verdegaal EM. Adoptive cell therapy: a highly successful individualized therapy for melanoma with great potential for other malignancies. Curr Opin Immunol. 2016 Apr;39:90–95. PubMed PMID: 26829458.
   PubMed Web of Science ®Google Scholar
• Khammari A, Labarriere N, Vignard V, et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol. 2009 Dec;129(12):2835–2842. PubMed PMID: 19554023.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016 Dec 8;375(23):2255–2262. PubMed PMID: 27959684; PubMed Central PMCID: PMCPMC5178827.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Iimmunol. 2004 Dec 15;173(12):7125–7130. PubMed PMID: 15585832; PubMed Central PMCID: PMCPMC2175171
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012 Nov-Dec;35(9):651–660. PubMed PMID: 23090074; PubMed Central PMCID: PMCPMC3501135.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012 Oct;12(10):671–684. PubMed PMID: 22996603.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009 Jul;15(7):808–813. PubMed PMID: 19525962; PubMed Central PMCID: PMCPMC2707501.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011 Sep 18;17(10):1290–1297. PubMed PMID: 21926977; PubMed Central PMCID: PMCPMC3192229.
   PubMed Web of Science ®Google Scholar
• Henning AN, Roychoudhuri R, Restifo NP. Epigenetic control of CD8(+) T cell differentiation. Nat Rev Immunol. 2018 May;18(5):340–356. PubMed PMID: 29379213.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007 Oct;12(10):1247–1252. PubMed PMID: 17962618.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Moreau P, San-Miguel JF, et al. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res off J Am Assoc Cancer Res. 2015 Nov 1;21(21):4767–4773. 10.1158/1078-0432.CCR-15-0530. PubMed PMID: 26362997
   PubMed Web of Science ®Google Scholar
• Lisiero DN, Soto H, Everson RG, et al. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. J Immunother Cancer. 2014;2:8. PubMed PMID: 25054063; PubMed Central PMCID: PMCPMC4105687.
   PubMedGoogle Scholar
• Yu T, Wang Y, Hu Q, et al. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget. 2017 Nov 17;8(58):98348–98359. PubMed PMID: 29228694; PubMed Central PMCID: PMCPMC5716734.
   PubMedGoogle Scholar
• Kagoya Y, Nakatsugawa M, Yamashita Y, et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016 Sep 1;126(9):3479–3494. PubMed PMID: 27548527; PubMed Central PMCID: PMCPMC5004946.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16;146(6):904–917. PubMed PMID: 21889194; PubMed Central PMCID: PMCPMC3187920.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53–65. PubMed PMID: 21741596; PubMed Central PMCID: PMCPMC4046888.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 1;109(1):31–39. PubMed PMID: 16960145; PubMed Central PMCID: PMCPMC1785068.
   PubMed Web of Science ®Google Scholar
• Mueller SN, Heath W, McLain JD, et al. Characterization of two TCR transgenic mouse lines specific for herpes simplex virus. Immunol Cell Biol. 2002 Apr;80(2):156–163. PubMed PMID: 11940116.
   PubMed Web of Science ®Google Scholar
• Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Iimmunol. 1998 Nov 15;161(10):5338–5346. PubMed PMID: 9820507
   PubMed Web of Science ®Google Scholar
• Lang A, Nikolich-Zugich J. Development and migration of protective CD8+ T cells into the nervous system following ocular herpes simplex virus-1 infection. J Iimmunol. 2005 Mar 1;174(5):2919–2925. PubMed PMID: 15728503
   PubMed Web of Science ®Google Scholar
• Wong DJ, Rao A, Avramis E, et al. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May;2(5):459–468. PubMed PMID: 24795358; PubMed Central PMCID: PMCPMC4010948.
   PubMed Web of Science ®Google Scholar
• Clutton G, Xu Y, Baldoni PL, et al. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. Sci Rep. 2016 Aug;2(6):30749. PubMed PMID: 27480951; PubMed Central PMCID: PMCPMC4969750.
   PubMed Web of Science ®Google Scholar
• Wozniak MB, Villuendas R, Bischoff JR, et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica. 2010 Apr;95(4):613–621. PubMed PMID: 20133897; PubMed Central PMCID: PMCPMC2857191.
   PubMed Web of Science ®Google Scholar
• Lin L, Jiang H, Huang M, et al. Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway. Oncol Rep. 2015 Aug;34(2):663–672. PubMed PMID: 26035691.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhu W, Peng Y, et al. The antitumor effects of vaccine-activated CD8(+) T cells associate with weak TCR signaling and induction of stem-like memory T cells. Cancer Immunol Res. 2017 Oct;5(10):908–919. PubMed PMID: 28851693; PubMed Central PMCID: PMCPMC5626646.
   PubMed Web of Science ®Google Scholar
• Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 2002 Nov 15;62(22):6438–6441. PubMed PMID: 12438231
   PubMed Web of Science ®Google Scholar
• Prlic M, Bevan MJ. Cutting edge: beta-catenin is dispensable for T cell effector differentiation, memory formation, and recall responses. J Iimmunol. 2011 Aug 15;187(4):1542–1546. PubMed PMID: 21724993; PubMed Central PMCID: PMCPMC3150307.
   PubMed Web of Science ®Google Scholar
• Sabatino M, Hu J, Sommariva M, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood. 2016 Jul 28;128(4):519–528. PubMed PMID: 27226436; PubMed Central PMCID: PMCPMC4965906.
   PubMed Web of Science ®Google Scholar
• Wylie B, Chee J, Forbes CA, et al. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. OncoImmunology. 2019;8(8):1609874.
   PubMed Web of Science ®Google Scholar
• Wylie B, Seppanen E, Xiao K, et al. Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103- and XCR1+CD103+ dendritic cells. Oncoimmunology. 2015 Aug;4(8):e1019198. PubMed PMID: 26405572; PubMed Central PMCID: PMCPMC4570138.
   PubMed Web of Science ®Google Scholar
• Wilson W. Varix/TumourGrowthAnalysis: tumour growth kinetics analysis. Zenodo. 2019. DOI:10.5281/zenodo.3341720
   Google Scholar